About This Page
This is a clinician-written, evidence-based summary aligned to the USMLE Step 2 CK Content Outline. It is intended for medical students preparing for USMLE Step 2 CK. Management reflects current ACC/AHA, USPSTF, and APA guidelines. Always cross-reference with UpToDate, institutional protocols, and clinical judgment.
The Bottom Line
- COPD diagnosis requires post-bronchodilator FEV1/FVC <0.70 in a patient with compatible symptoms or exposure
- Smoking is the major risk factor; alpha-1 antitrypsin deficiency causes early emphysema, especially basilar panacinar disease
- Stable COPD therapy is symptom and exacerbation based: bronchodilators first, inhaled corticosteroids for selected patients with frequent exacerbations or eosinophilia
- Acute exacerbation: short-acting bronchodilators, systemic steroids, antibiotics when sputum purulence or ventilatory support is present
- Long-term oxygen improves survival only when severe chronic resting hypoxemia is present
Overview
Chronic obstructive pulmonary disease is a preventable and treatable disease characterized by persistent airflow limitation due to airway and/or alveolar abnormalities. Chronic bronchitis is defined clinically by productive cough for at least 3 months in each of 2 consecutive years. Emphysema is defined pathologically by destruction of alveolar walls and loss of elastic recoil. GOLD emphasizes spirometric confirmation, exacerbation risk, symptom burden, smoking cessation, vaccination, pulmonary rehabilitation, and individualized inhaled therapy.
Epidemiology
COPD affects approximately 16 million diagnosed adults in the United States, with additional undiagnosed cases. It is a leading cause of death and hospitalization. Cigarette smoking is the dominant risk factor, but biomass exposure, occupational dust and fumes, air pollution, childhood lung development, asthma, and alpha-1 antitrypsin deficiency also contribute. COPD prevalence increases with age and is associated with cardiovascular disease, lung cancer, osteoporosis, depression, and frailty.
Clinical Features
Symptoms
Progressive exertional dyspnea
Chronic productive cough and sputum production
Wheezing and chest tightness
Frequent winter bronchitis or recurrent exacerbations
Weight loss, fatigue, and reduced exercise tolerance in advanced disease
Acute worsening dyspnea with increased sputum volume or purulence
Signs
Prolonged expiratory phase and diffuse wheeze
Barrel chest, hyperresonance, and reduced breath sounds
Pursed-lip breathing and accessory muscle use
Cyanosis or oxygen desaturation
Signs of cor pulmonale: elevated JVP, hepatomegaly, peripheral edema
Altered mental status or asterixis from hypercapnia
Investigations
First-line
Post-bronchodilator spirometryRequired for diagnosis. FEV1/FVC <0.70 confirms persistent airflow obstruction; FEV1 percent predicted grades severity
Pulse oximetryAssess hypoxemia at rest and exertion. Severe resting hypoxemia prompts ABG and oxygen assessment
Chest X-rayHyperinflation, flattened diaphragms, increased retrosternal airspace, or bullae; also evaluates pneumonia, pneumothorax, and heart failure
Second-line
ABGUse in severe exacerbation, altered mental status, suspected hypercapnia, or oxygen saturation <92%
Alpha-1 antitrypsin levelTest at least once in all COPD patients, especially age <45, minimal smoking history, basilar emphysema, or family history
CT chestNot routine for diagnosis; useful for lung cancer screening, bronchiectasis, bullae, or pre-procedure planning
Specialist
6-minute walk testFunctional assessment and exertional desaturation; helps pulmonary rehab and oxygen planning
Full PFTs with DLCODLCO is reduced in emphysema; lung volumes show air trapping and hyperinflation
1
Core measures
- Smoking cessation is the only intervention that slows long-term FEV1 decline
- Vaccination: influenza annually, COVID-19, pneumococcal per CDC age and risk guidance, RSV vaccine in eligible older adults
- Pulmonary rehabilitation for symptomatic patients and after hospitalization for exacerbation
- Assess inhaler technique and adherence at every visit
- Treat comorbidities including CAD, heart failure, anxiety, depression, osteoporosis, OSA, and lung cancer risk
2
Stable inhaled therapy
- Low symptoms and low exacerbation risk: short-acting bronchodilator as needed
- Persistent dyspnea: long-acting bronchodilator, usually LAMA or LABA
- High symptoms: LAMA/LABA combination is preferred
- Frequent exacerbations with elevated blood eosinophils or asthma overlap: add ICS, usually as triple therapy LABA/LAMA/ICS
- Avoid ICS monotherapy in COPD; ICS increases pneumonia risk and is most useful when eosinophils are high or exacerbations persist
3
Acute exacerbation
- Inhaled albuterol with or without ipratropium
- Prednisone 40 mg daily for 5 days or equivalent systemic corticosteroid
- Antibiotics if increased sputum purulence plus increased dyspnea or volume, or if mechanical ventilation is required
- Controlled oxygen target SpO2 88-92% to avoid worsening hypercapnia
- Noninvasive ventilation for acute hypercapnic respiratory failure with acidosis unless contraindicated
4
Advanced disease
- Long-term oxygen if PaO2 <=55 mmHg or SaO2 <=88%, or PaO2 56-59 with pulmonary hypertension, cor pulmonale, or hematocrit >55%
- Roflumilast for chronic bronchitis phenotype with severe obstruction and frequent exacerbations
- Long-term azithromycin may reduce exacerbations in former smokers with frequent exacerbations, but monitor QT prolongation and hearing loss
- Consider lung volume reduction, endobronchial valves, bullectomy, or transplant in carefully selected patients
Complications
- Acute exacerbation: Often triggered by viral infection, bacterial infection, or air pollution
- Respiratory failure: Hypoxemic and/or hypercapnic failure with acidosis in severe disease
- Cor pulmonale: Pulmonary hypertension from chronic hypoxic vasoconstriction
- Pneumothorax: Ruptured bleb or bullae can cause sudden dyspnea and pleuritic pain
- Lung cancer: COPD independently increases risk, especially in smokers
- Cachexia and osteoporosis: Advanced systemic effects and corticosteroid exposure increase morbidity
USMLE Step 2 CK Exam Tips
- 1COPD diagnosis is not clinical alone: post-bronchodilator FEV1/FVC <0.70 is required
- 2Alpha-1 antitrypsin deficiency = young patient, minimal smoking, basilar panacinar emphysema, liver disease
- 3Long-term oxygen is the COPD intervention that improves survival in severe chronic resting hypoxemia
- 4Acute COPD exacerbation with pH <7.35 and elevated PaCO2 = noninvasive ventilation unless contraindicated
- 5Oxygen target in COPD exacerbation is 88-92%, not 100%
- 6ICS in COPD reduces exacerbations in selected patients but increases pneumonia risk
- 7Chronic bronchitis = productive cough for 3 months in each of 2 consecutive years
practicetest your knowledge on copdApply what you've learnt with USMLE Step 2 CK-style questions from the iatroX Q-Bank — respiratory and beyond.
open q-bank